rc48-adc
Acute Myeloid Leukemia With Positive Minimal Residual Disease
SillaJen, Inc.antibody_drug_conjugatePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Acute Myeloid Leukemia With Positive Minimal Residual Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tislelizumab Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | BB |
Pyrotinib SillaJen, Inc. | Phase 2 | B |
Same molecule, other indications
rc48-adc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →